Answers are grounded in this paper and cite their sources.
// Li-Ching Fan 1, 2 , Hao-Wei Teng 3, 7 , Chung-Wai Shiau 4 , Wei-Tien Tai 1, 2 , Man-Hsin Hung 5, 7 , Shung-Haur Yang 6, 7 , Jeng-Kai Jiang 6, 7 , Kuen-Feng Chen 1, 2 1 Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan 2 National Center of Excellence for Clinical Trial and Research, National Taiwan University Hospital, Taipei, Taiwan 3 Division of Hematology and Oncology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan 4 Institute of Biopharmaceutical Sciences, National Yang-Ming University, Taipei, Taiwan 5 Division of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan 6 Division of Colon and Rectal Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan 7 School of Medicine, National Yang-Ming University, Taipei, Taiwan Correspondence to: Kuen-Feng Chen, email: kfchen1970@ntu.edu.tw Keywords: regorafenib, EMT, SHP-1, STAT3, CRC Received: March 11, 2016 Accepted: August 13, 2016 Published: August 26, 2016 ABSTRACT Epithelial-to-mesenchymal transition (EMT) is well-known to evoke cancer invasion/metastasis, leading to a high frequency of mortality in patients with metastatic colorectal cancer (mCRC). Protein tyrosine phosphatase (PTPase)-targeted therapy has been identified as a novel cancer therapeutic. Previously, we proved that sorafenib with anti-EMT potency prevents TGF-β1-induced EMT/invasion by directly activating SH2-domain-containing phosphatase 1 (SHP-1)-dependent p-STAT3 Tyr705 suppression in hepatocellular carcinoma. Regorafenib has a closely related chemical structure as sorafenib and is approved for the pharmacotherapy of mCRC. Herein, we evaluate whether regorafenib activates PTPase SHP-1 in the same way as sorafenib to abolish EMT-related invasion/metastasis in CRC. Notably, regorafenib exerted potent anti-EMT activity to curb TGF-β1-induced EMT/invasion in vitro as well inhibited lung metastatic outgrowth of SW480 mesenchymal cells in vivo . Mechanistically, regorafenib-enhanced SHP-1 activity significantly impeded TGF-β1-induced EMT/invasion via low p-STAT3 Tyr705 level as proved by a SHP-1 inhibitor or siRNA-mediated SHP-1 depletion. Conversely, overexpression of SHP-1 further enhanced the inhibitory effects of regorafenib on TGF-β1-induced p-STAT3 Tyr705 and EMT/invasion. Regorafenib directly activates SHP-1 by potently relieving the autoinhibited N-SH2 domain of SHP-1 to inhibit TGF-β1-induced p-STAT3 Tyr705 and EMT/invasion. Importantly, the clinical evidence indicated that SHP-1 was positively correlated with E-cadherin and that significantly determined the overall survival of CRC patients. This result further confirms our in vitro data that SHP-1 is a negative regulatory PTPase in EMT regulation and serves as a pharmacological target for mCRC therapy. Collectively, activating PTPase SHP-1 by regorafenib focusing on its anti-EMT activity might be a useful pharmacotherapy for mCRC.
No takes yet. Share an insight, caveat, or question.
Fan et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: